Himanshu Agarwal, MD

Department

Medicine

Position

Assistant Professor

Articles

• N Engl J Med
  Schwartz GG, Steg PG, , Zeiher AM. Agarwal H , et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018 Nov 29;379(22):2097-2107 2021
• Lancet Diabetes Endocrinol
  Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol J Am Coll Cardiol 2021 Aug 3;78(5):421-433. Gregory G Schwartz 1 , Michael Szarek 2 , Vera A Bittner, H. Agarwal et al. ODYSSEY Outcomes Committees and Investigators. 2021
• Journal of American College of Cardiology
  Predictors of Device-Related Thrombus Following Percutaneous Left Atrial Appendage Occlusion: Simard T, Jung , Alkhouli M, Agarwal H et.al Journal of American College of Cardiology ; Volume 78, Issue 4Pages A1-A36, e19-e24, 297-420, (27 July 2021 2021
• Diabetes Care
  Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. Schwartz GG, Szarek M, Bittner VA, Bhatt DL, Diaz R, Goodman SG, Jukema JW, Loy M, Manvelian G, Pordy R, White HD, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Diabetes Care. 2021 May;44(5):1219-1227. 10.2337/dc20-2842 2021
• JACC Case Report
  Left Atrial Appendage Closure in a Patient With a Patent Foramen Ovale Septal Occluder Device Omar Kousa 1 , Toufik Mahfood-Haddad 1 , Shantanu M Patil 1 , Himanshu Agarwal 1 , Hussam Abuissa ACC Case Rep 2021 Mar 17;3(3):508-511 2021
• Heart Rhythm Case Reports
  Left atrial appendage closure in a patient with situs inversus totalis and interrupted inferior vena cava - A transhepatic approach.Tandon TS, Agarwal H, Alla VM, Abuissa HS. HeartRhythm Case Rep. 2020 Sep 15;6(11):871-874. 2020
• J American College of Cardiology Cardiovascular Interv
  Van Mieghem NM, Popma JJ, Reardon M, Agarwal, H et al . Complete 2-Year Results Confirm Bayesian Analysis of the SURTAVI Trial. JACC Cardiovasc Interv2020 Feb 10;13(3):323-33 2020
• Lancet Diabetes Endocrinol
  Ray KK, Colhoun HM, Szarek M, Steg PG, Agarwal H et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628 2019
• J American College of Cardiology Cardiovascular Interv
  Massive Inferior Vena Cava Thrombosis Associated With Retroperitoneal Venolymphatic Malformation Raviteja R. Guddeti, Geetanjali Dang MD, Abilash AkinapelliMD, Himanshu AgarwalMD and Joseph StavasMD J Am Coll Cardiol Cardiovasc Interv. 2018 Nov, 11 (22) e187–e188. 2018
• J Am Coll Cardiol
  Outcomes of Drug-Eluting versus Bare-Metal Stents in Saphenous Vein Graft Lesions: A Meta-Analysis of Randomized Controlled Trials Toufik Mahfood Haddad, Aravdeep Jhand, Jai Parekh, Luay Sarsam, Abdul Saadi, Aiman Smer, Himanshu Agarwal, Michael Delcore and Venkata M. Alla. J Am Coll Cardiol. 2018 Sep, 72 (13_Supplement) B112 2018
• N Engl J Med
  Reardon MJ, Van Mieghem NM, , Kappetein AP Agarwal H; .et.al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. Second Generation Versus First Generation Transcatheter Aortic Valve Replacement: A Meta-analysis :N Engl J Med. 2017 Apr 6;376(14):1321-1331 2017
• J Am Coll Cardiol
  Arun Kanmanthareddy, Dixitha Anugula, Sameer Gafoor, Rahul Sharma, Claire Hunter, Scott Lilly, Michael White, Michael Del Core, Himanshu Agarwal, Dennis Esterbrooks, Aryan Mooss and Venkata Alla. J Am Coll Cardiol Cardiovasc Interv. 2017 Feb, 10 (3_Supplement) S71 2017

Other

• CHAMPION AF: Principal Investigator WATCHMAN FLX versus DOAC for Embolic Protection in the Management of Non-Valvular Atrial Fibrillation (NVAF) Patients

• CATALYST AF : Principal investigator. Amplatzer Amulet vs NOAC for Stroke prevention in patients of Non Valvular Atrial Fibrillation

• PROTECTED-TAVR: PrincipalInvestigator, Stroke PROTECTion with SEntinel During Transcatheter Aortic Valve Replacement

• WATCH-TAVR: Principal Investigator WATCHMAN For Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement (TAVR)